Lantheus Discloses Merger Litigation and Supplemental Proxy Details Ahead of October 14 Vote
LNTH has more than doubled off its 52-week low of $49.67.
Summary
Lantheus disclosed three new stockholder lawsuits and sixteen demand letters challenging its $8B Curium merger proxy, and issued supplemental disclosures quantifying Morgan Stanley's valuation ranges and its 2–3% stock ownership stake.
Key Events · Legal and Risk Events · LNTH
-
Three New Merger Lawsuits Filed
Hamilton, McDaniels, and Garfield complaints filed in New York and Massachusetts courts allege the definitive proxy omits or misrepresents financial projections, Morgan Stanley's fairness opinion, and insider conflicts.
-
Sixteen Stockholder Demand Letters
As of September 30, 2026, Lantheus received sixteen demand letters seeking additional disclosures, with two attaching draft complaints.
-
Supplemental Valuation Disclosures
Morgan Stanley's DCF analysis implied $88.10–$118.60 per share; comparable companies analysis implied $63.85–$84.20 per share, based on 68.2M fully diluted shares.
-
Morgan Stanley Ownership Conflict Revealed
Morgan Stanley held a 2–3% aggregate interest in Lantheus common stock as of August 3, 2026, a potential conflict not previously disclosed.
Analysis · LNTH · Life Sciences
Three stockholder lawsuits and sixteen demand letters now challenge the $8 billion Curium acquisition, alleging the proxy omitted key details on financial projections, Morgan Stanley's fairness analysis, and insider conflicts. Lantheus denies the claims but issued supplemental disclosures to avoid delaying the October 14 special meeting vote. The new details quantify Morgan Stanley's valuation ranges — $88.10 to $118.60 per share on a DCF basis and $63.85 to $84.20 on a comparable companies basis — and reveal Morgan Stanley held a 2–3% stake in Lantheus stock, a potential conflict not previously disclosed. While the merger remains on track, the litigation adds execution risk and the supplemental disclosures give shareholders materially more information to evaluate the deal.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1531 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $99.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $49.67 to $111.86. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.